We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+13.2%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$581M
AUM Growth
+$65.9M
Cap. Flow
-$17.7M
Cap. Flow %
-3.04%
Top 10 Hldgs %
83.03%
Holding
29
New
5
Increased
5
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$31M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$9.66M
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$7.26M
4
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$6.78M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.44M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$21.1M
2
ARRY
Array Biopharma Inc
ARRY
+$8.39M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$7.51M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$2.72M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$931K

Sector Composition

Rank Sector Weight
1 Healthcare 79.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$5.94B
$136M 23.48%
5,055,325
-750,204
-13% -$21.1M
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$614M
$93.6M 16.1%
9,427,897
+3,156,339
+50% +$31M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$60.5M 10.4%
9,719,589
-1,412,269
-13% -$8.39M
RIGL icon
4
Rigel Pharmaceuticals
RIGL
$704M
$34.8M 5.99%
973,070
– –
GYRE icon
5
Gyre Therapeutics
GYRE
$648M
$32.8M 5.64%
7,837
– –
CCXI
6
DELISTED
ChemoCentryx, Inc.
CCXI
$29.9M 5.14%
5,377,616
+350,850
+7% +$3.79M
CASC
7
DELISTED
Cascadian Therapeutics, Inc.
CASC
$18.3M 3.14%
1,478,796
+129,916
+10% +$1.37M
EXEL icon
8
Exelixis
EXEL
$14.1B
$14.6M 2.51%
2,502,256
– –
CYTK icon
9
Cytokinetics
CYTK
$10.9B
$13M 2.24%
1,718,905
– –
TBRA
10
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$11.1M 1.91%
+184,343
New +$9.66M
QLTI
11
DELISTED
QLT Inc
QLTI
$11M 1.89%
2,370,263
– –
AVNR
12
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$10.3M 1.78%
2,436,053
+1,430,000
+142% +$6.78M
RCPT
13
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$8.31M 1.43%
320,000
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.26M 1.42%
+545,372
New +$5.36M
ARQL
15
DELISTED
Arqule Inc
ARQL
$6.84M 1.18%
2,935,187
+302,755
+12% +$760K
FLNA
16
Filana Therapeutics
FLNA
$46.4M
$6.41M 1.1%
336,761
– –
OMED
17
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$6M 1.03%
+391,800
New +$7.26M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$1.95B
$5.51M 0.95%
+196,996
New +$5.44M
PTN
19
Palatin Technologies
PTN
$13.9M
$3.51M 0.6%
4,160
– –
SPHS
20
DELISTED
Sophiris Bio, Inc.
SPHS
$2.81M 0.48%
+600,000
New +$2.77M
ANTH
21
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.25M 0.39%
69,953
– –
RGLS
22
DELISTED
Regulus Therapeutics
RGLS
$2.2M 0.38%
1,947
-273
-12% -$322K
GNVC
23
DELISTED
GenVec, Inc.
GNVC
$617K 0.11%
48,610
– –
PRTK
24
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$477K 0.08%
12,500
– –
AVDL
25
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-151,406
Closed -$931K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2013 Portfolio in Review

As of Q3 2013, BVF Inc held 29 positions worth $581M, up 13% from $515M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

BVF Inc withdrew a net $17.7M in Q3 2013, closing 3 positions and reducing 3 holdings. Its most notable exit was Portola Pharmaceuticals, Inc., an estimated $7.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 71% a quarter earlier.

Against the trend, BVF Inc opened a new position in Tobira Therapeutics, Inc. Common Stock worth $11.1M.

  • BVF Inc's largest Q3 2013 buy was Tobira Therapeutics, Inc. Common Stock: 184,343 shares worth $11.1M.
  • BVF Inc added most to Ironwood Pharmaceuticals in Q3 2013, an estimated $31M increase.
  • BVF Inc's biggest Q3 2013 reduction was Ligand Pharmaceuticals, cutting an estimated $21.1M.
  • BVF Inc fully exited Portola Pharmaceuticals, Inc. in Q3 2013, selling an estimated $7.51M.
  • BVF Inc's ten largest holdings make up 83% of its $581M portfolio in Q3 2013.
  • BVF Inc opened 5 new positions and closed 3 in Q3 2013.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $581M.

Based on BVF Inc's 13F filing for Q3 2013, filed 14 Nov 2013.